Lysophosphatidic Acid Modifies the Response of PC3 Prostate Cancer Cells to Chemotherapeutics
OBJECTIVE: Prostate cancer is the most frequently diagnosed cancer among men. Docetaxel, estramustine, and mitoxantrone are commonly used chemotherapy agents for the treatment of prostate cancer. However, lysophosphatidic acid (LPA), a biologically active glycerophospholipid derivative, induces prol...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Verduci Editore
2020-09-01
|
| Series: | World Cancer Research Journal |
| Subjects: | |
| Online Access: | https://www.wcrj.net/wp-content/uploads/sites/5/2020/11/e1687.pdf |